PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer [Yahoo! Finance]
Puma Biotechnology, Inc. (NASDAQ: PBYI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer [Yahoo! Finance]
Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative [Yahoo! Finance]